Long COVID Burden Has Decreased Over Time in Health Care Workers
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, Jan. 10, 2025 -- The prevalence and burden of post-acute sequelae of COVID-19 (PASC) has decreased over time in health care workers, according to a study published online Nov. 12 in Infection.
Tamara Dörr, M.D., from the Cantonal Hospital St. Gallen in Switzerland, and colleagues assessed the burden and course of PASC in health care workers during a 30-month period. The analysis included survey responses from 1,704 health care workers.
The researchers found that 30.7 percent reported one or more PASC symptom in October 2023, with 6.7 percent reporting having PASC currently or in the past. Compared with other variants, PASC symptoms were most common after Wild-type infection. More than one in seven (15 percent) indicated relevant/severe restrictions in their daily activities and nearly three-quarters (74 percent) tried at least one measure against their symptoms, with 81 percent reporting having benefitted.
"Our data show a steady and continuing decrease of PASC prevalence and burden in a health care worker population of predominantly female, and previously healthy individuals over the course of 30 months," the authors write. "Choice and benefit of therapeutic measures vary considerably; however, recovery rate is high after 30 months and seems to be time-dependent."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-01-11 12:00
Read more
- Allergies Have You Stuffed Up? Nose Fungi May Be to Blame
- Avoiding Isolation By Volunteering Offers Mental Health Benefits to Seniors
- Study Supports HPV Self-Testing for Cervical Cancer Screening
- 2013 to 2022 Saw Increase in Influenza Testing at Hospital ED Visits
- GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea
- FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions